Hormonal intrauterine device

Search ⌘K Suggest Edit Sign in Overview and device characteristics Clinical indications and efficacy Safety and contraindications Adverse effects and long-term outcomes Mechanisms of action Insertion, management, and removal Historical development Controversies and alternative perspectives References Fact-checked by Grok 4 months ago Hormonal intrauterine device A hormonal intrauterine device (IUD) is a T-shaped plastic contraceptive device inserted into the uterus that continuously releases progestin, most commonly levonorgestrel, to prevent pregnancy primarily by thickening cervical mucus to block sperm transport and inducing endometrial atrophy to inhibit implantation, with ovulation suppression occurring in a subset of cycles.[1][2] These devices offer highly effective long-acting reversible contraception, with first-year typical-use failure rates below 0.2%, and durations of action ranging from 3 to 8 years based on the hormone dosage and specific formulation.[1][2] Beyond contraception, hormonal IUDs are approved for managing heavy menstrual bleeding, where the local progestin effect markedly reduces endometrial proliferation and blood loss, often leading to amenorrhea in up to 20% of users within the first year.[2][3] Insertion requires a brief outpatient procedure by a trained healthcare provider, rendering the method reversible upon removal, with fertility typically returning promptly thereafter due to the localized hormone delivery minimizing systemic impacts.[2] Empirical data from clinical trials affirm their safety profile, with low rates of serious adverse events such as uterine perforation (approximately 1 in 1,000 insertions) or pelvic inflammatory disease primarily linked to insertion rather than ongoing use.[1][2] However, initial irregular bleeding, spotting, or amenorrhea affects many users, alongside potential progestin-related effects like headaches, acne, or mood alterations, which contribute to discontinuation in 5-15% of cases within the first year; long-term studies indicate no elevated risks of infertility, ectopic pregnancy, or malignancy beyond baseline population rates.[1][2][4] Overview and device characteristics Description and types A hormonal intrauterine device (IUD), also known as a levonorgestrel-releasing intrauterine system (LNG-IUS), is a small, T-shaped plastic contraceptive device inserted into the uterus by a healthcare provider to prevent pregnancy.[5] The device consists of a polyethylene frame with a hormone reservoir containing levonorgestrel, a synthetic progestin, embedded in a silicone matrix covered by a rate-controlling membrane that allows for gradual release into the uterine cavity.[5] It measures approximately 32 mm in height and width for standard models, with flexible arms that conform to the uterine shape upon insertion via a dedicated inserter tube.[6] Four principal types of hormonal IUDs are approved for use in the United States, all releasing levonorgestrel but differing in total hormone load, initial daily release rate, approved duration of use, and physical dimensions to accommodate varying uterine sizes.[7] Brand Hormone Load (mg) Initial Release Rate (mcg/day) Approved Duration (years) Dimensions (height x width, mm) Notes Mirena 52 20 8 32 x 32 Higher dose; also indicated for heavy menstrual bleeding.[5][7] Liletta 52 20 8 32 x 32 Similar to Mirena in dosing and size.[8][7] Kyleena 19.5 17.5 5 30 x 28 Smaller size for narrower uteri; lower overall hormone exposure.[7][6] Skyla 13.5 14 3 30 x 28 Smallest device; lowest hormone load, suitable for nulliparous women.[7][6] These variations allow selection based on patient anatomy, desired duration, and tolerance for systemic hormone effects, with smaller, lower-dose options like Skyla and Kyleena often preferred for adolescents or those with smaller uteri.[7] All types include monofilament strings for removal and verification of placement.[9] Composition and hormone release kinetics Hormonal intrauterine devices, also known as levonorgestrel-releasing intrauterine systems (LNG-IUS), feature a T-shaped frame constructed from polyethylene, with the horizontal arms incorporating barium sulfate for radiographic visibility. The vertical stem houses a cylindrical reservoir containing levonorgestrel (LNG), a synthetic progestin, dispersed within a polydimethylsiloxane (PDMS, silicone) matrix at concentrations such as 52 mg total in the Mirena system. This reservoir is encased by a semi-permeable PDMS membrane that regulates hormone diffusion into the uterine cavity.[10][11] The hormone release kinetics follow a diffusion-controlled mechanism, characterized by an initial higher release rate that progressively diminishes over the device's lifespan due to matrix depletion and reduced concentration gradients. For the Mirena LNG-IUS (52 mg), the initial in vivo release averages approximately 20-21 mcg of LNG per day, declining to about 15 mcg/day by the fifth year and further to 6.5-7 mcg/day after eight years, with an overall average of around 13.5 mcg/day. Lower-dose variants, such as Kyleena (19.5 mg LNG), exhibit correspondingly reduced initial rates of about 17.5 mcg/day, tapering to 7.4 mcg/day over five years.[5][12][13] These kinetics result in localized endometrial exposure far exceeding systemic levels, with plasma LNG concentrations typically ranging from 150-200 pg/mL initially for Mirena, stabilizing below 100 pg/mL long-term, minimizing ovulation suppression in most users while achieving contraceptive efficacy through cervical mucus thickening and endometrial atrophy. Pharmacokinetic studies confirm the release profile's consistency across users, though individual variations arise from factors like uterine size and insertion depth.[14][15][16] Clinical indications and efficacy Contraceptive uses and effectiveness rates Hormonal intrauterine devices, primarily levonorgestrel-releasing intrauterine systems (LNG-IUS), serve as long-acting reversible contraceptives inserted into the uterine cavity to prevent pregnancy over extended periods ranging from 3 to 8 years, depending on the formulation. These devices deliver progestin directly to the endometrium and cervical canal, minimizing systemic exposure compared to oral contraceptives. Common brands include Mirena (52 mg levonorgestrel, approved for up to 8 years), Liletta (52 mg, up to 8 years), Kyleena (19.5 mg, 5 years), and Skyla (13.5 mg, 3 years).00366-0/fulltext)[17] The contraceptive action primarily involves local effects: thickening of cervical mucus to block sperm ascent into the uterus, inhibition of sperm capacitation and survival, and endometrial atrophy that reduces receptivity to implantation. Ovulation suppression occurs in 20-45% of users but is not the dominant mechanism, as fertility resumes promptly upon removal, indicating no permanent ovarian impact. These effects result in negligible user-dependent failure rates, distinguishing LNG-IUS from methods requiring daily adherence.[5][18] Effectiveness is among the highest of reversible methods, with first-year typical-use failure rates under 0.3%, comparable to sterilization. Clinical trials report Pearl Indexes (pregnancies per 100 woman-years) of 0.11-0.28 for initial years across formulations, reflecting rare method failures like expulsion or undetected malposition. Cumulative 5-year pregnancy rates for the 52-mg LNG-IUS are approximately 0.7%, with extension studies confirming ongoing efficacy to 8 years at under 1% cumulative failure, based on life-table analyses from large cohorts exceeding 1,000 participants. Lower-dose systems like Kyleena and Skyla show similar first-year efficacy, though shorter durations limit direct long-term comparisons.[19]00234-2/fulltext)[17] Device Levonorgestrel Dose Approved Duration First-Year Pearl Index Cumulative Long-Term Failure Rate Mirena 52 mg 8 years 0.20 <1% at 8 years [19]00366-0/fulltext) Liletta 52 mg 8 years 0.18 <1% at 8 years [20] Kyleena 19.5 mg 5 years 0.28 0.34% at 5 years [17] Skyla 13.5 mg 3 years 0.33 <1% at 3 years 00234-2/fulltext) Factors influencing effectiveness include timely insertion post-menses or abortion to avoid pre-existing pregnancy, and verification of placement via ultrasound if expulsion is suspected, which occurs in 2-5% of cases within the first year. Real-world data from registries corroborate trial results, with no evidence of diminished efficacy from body weight or parity variations.[21] Non-contraceptive medical applications The levonorgestrel-releasing intrauterine system (LNG-IUS) exerts localized progestogenic effects on the endometrium, enabling its use for non-contraceptive indications such as reducing excessive menstrual bleeding and providing opposition to unopposed estrogen in hormone replacement therapy (HRT).[22] These applications stem from the device's ability to induce endometrial atrophy and suppress proliferation, with minimal systemic hormone absorption compared to oral progestogens.[23] Clinical guidelines in regions like the UK endorse LNG-IUS for heavy menstrual bleeding (HMB) as a first-line option after conservative measures fail, based on randomized controlled trials demonstrating superior bleeding control over alternatives like tranexamic acid or nonsteroidal anti-inflammatory drugs.[24] In the treatment of idiopathic or structural HMB, LNG-IUS significantly diminishes menstrual blood loss, with randomized trials reporting mean reductions of 86% at 3 months and 97% at 6 months post-insertion.[22] Amenorrhea rates reach 95% by 2 years in retrospective cohorts of perimenopausal women, often averting hysterectomy in over 60% of cases.[24] These outcomes arise from direct endometrial transformation, though initial irregular bleeding may occur in up to 20% of users, contributing to discontinuation rates of 10-15% within the first year.[22] Use in Menopausal Hormone Therapy Beyond contraception and heavy menstrual bleeding management, the levonorgestrel-releasing intrauterine system (LNG-IUS, e.g., Mirena) is widely used off-label or per guidelines as the progestogen component in combined menopausal hormone therapy (HRT) for women with an intact uterus. It provides localized progestin to oppose estrogen's proliferative effects on the endometrium, preventing hyperplasia and cancer risk while minimizing systemic progestin exposure. In this regimen, the IUS is paired with systemic estrogen (transdermal preferred for lower VTE risk), allowing continuous estrogen administration without daily progestogen dosing. The device is effective for endometrial protection for up to 5 years in HRT (requiring replacement thereafter if HRT continues). Benefits include reduced progestin side effects (e.g., less mood alteration, breast tenderness), no daily medication, and frequent amenorrhea after initial adjustment. It is particularly useful for perimenopausal women needing contraception or bleeding control alongside symptom relief from estrogen. It does not relieve estrogen-deficiency symptoms like hot flashes or night sweats due to local progestin release, and amenorrhea may mask menopause, requiring follicle-stimulating hormone testing for confirmation. Side effects in HRT users mirror general LNG-IUS effects: initial irregular bleeding/spotting (often resolving), possible headaches, acne, or pelvic cramping. Guidelines (NHS, menopause societies) endorse this approach for suitable candidates. LNG-IUS also addresses symptoms of endometriosis and adenomyosis, particularly dysmenorrhea and chronic pelvic pain, through endometrial suppression and reduced lesion activity. Prospective studies report visual analog scale pain scores dropping from 7.7 to 2.7 over 36 months in endometriosis patients, with 59% continuing use long-term.[22] A Cochrane review of postoperative LNG-IUS in symptomatic endometriosis found low-certainty evidence for dysmenorrhea relief (e.g., median VAS reduction of 81 mm vs. 50 mm at 12 months compared to expectant management) and possible quality-of-life gains, though imprecision and bias risks limit conclusions.[25] For endometrial hyperplasia, observational data indicate 90% regression rates at 24 months, supporting its role in atypical cases as an alternative to oral therapy.[22] Evidence for uterine fibroids remains inconsistent, with volume reductions in select trials but no reliable impact on obstructive symptoms.[22] Overall, while effective for bleeding disorders, applications in inflammatory conditions rely on smaller cohorts, warranting individualized assessment.[22] Use in special populations The levonorgestrel-releasing intrauterine system (LNG-IUS) is safe and effective for contraception and menstrual management in adolescents and nulliparous women, with efficacy rates comparable to those in parous women despite higher initial expulsion risks of up to 10-15% in younger users.[26] [27] Clinical guidelines from the American College of Obstetricians and Gynecologists endorse its use in this population, noting noncontraceptive benefits such as reduced menorrhagia and dysmenorrhea.[27] 00417-X/fulltext) Insertion challenges may be greater due to cervical stenosis, but long-term continuation rates exceed 80% at one year, with satisfaction driven by amenorrhea in over 50% of users.[28] In breastfeeding women, LNG-IUS insertion, including immediate postpartum placement within 10 minutes of placental delivery, does not adversely affect lactation success, infant growth, or breastfeeding duration, as evidenced by noninferiority trials showing no differences in milk production or prolactin levels compared to delayed insertion.[29] 30277-9/fulltext) The U.S. Medical Eligibility Criteria classify it as Category 2 (advantages outweigh risks) for initiation at 4 weeks postpartum or later in breastfeeding individuals, with plasma levonorgestrel levels sufficient for local endometrial effects without systemic interference.[30] Studies report breastfeeding continuation rates above 90% at 6 months post-insertion.[31] For perimenopausal women, the LNG-IUS effectively manages heavy menstrual bleeding and provides contraception until menopause confirmation, reducing blood loss by 80-90% and inducing amenorrhea in 40-60% within the first year, while allowing endometrial protection without unopposed estrogen risks.[32] [33] It does not alter the onset of menopause but facilitates symptom relief through localized progestin delivery, with extension beyond 5 years supported for ongoing bleeding control.[34] In obese women (BMI ≥30 kg/m²), the LNG-IUS maintains contraceptive efficacy above 99%, though plasma levonorgestrel concentrations are 20-30% lower than in non-obese users due to increased volume of distribution, without impacting pregnancy rates over 5-7 years.[35] 30738-6/fulltext) Expulsion rates may rise to 10-15% in class III obesity (BMI ≥40 kg/m²), necessitating closer follow-up, but overall complication profiles remain favorable compared to systemic progestins.[36] It is particularly beneficial for endometrial hyperplasia prevention in this high-risk group, with cost-effectiveness analyses favoring its use over oral alternatives.00165-7/abstract) In women with polycystic ovary syndrome (PCOS), LNG-IUS use shows minimal adverse metabolic effects, with limited specific evidence for lower-dose Kyleena (19.5 mg levonorgestrel). Studies on higher-dose systems like Mirena (52 mg) report small increases in fasting glycemia and abdominal circumference but reductions in LDL and total cholesterol, with no significant overall clinical or metabolic changes over up to 24 months. LNG-IUS is considered safe and effective with neutral to minimal metabolic impact in this population.[37][38] Safety and contraindications Absolute and relative contraindications Absolute contraindications for hormonal intrauterine devices (IUDs), such as levonorgestrel-releasing systems like Mirena, include conditions where the risks substantially outweigh any potential benefits, rendering insertion unacceptable. These encompass known or suspected pregnancy, as the device must not be placed in a gravid uterus due to risks of miscarriage or fetal harm.[39] Active pelvic inflammatory disease (PID) or acute genital tract infections, including untreated cervicitis, vaginitis, or sexually transmitted infections like gonorrhea or chlamydia, are prohibited to avoid exacerbating infection or sepsis.[39] [9] Known or suspected breast cancer or other progestin-sensitive malignancies, such as endometrial or ovarian carcinoma, contraindicate use due to potential hormonal stimulation of tumor growth.[39] [9] Uterine or cervical neoplasia, unresolved abnormal Pap smears, or cervical cancer similarly preclude insertion owing to risks of worsening malignancy or diagnostic interference.[39] Congenital or acquired uterine anomalies resulting in a distorted uterine cavity prevent proper placement and increase expulsion or perforation risks.[39] Postpartum or postabortion endometritis or sepsis within the prior three months heightens infection risk.[39] Acute liver disease, benign or malignant liver tumors, or severe decompensated cirrhosis are absolute barriers due to impaired progestin metabolism.[39] Hypersensitivity to levonorgestrel or device components, and unexplained abnormal uterine bleeding, also qualify as contraindications to avoid allergic reactions or undiagnosed pathology.[39] Relative contraindications involve scenarios where insertion may be considered if benefits outweigh risks, often requiring careful evaluation, screening, or alternatives, per U.S. Medical Eligibility Criteria (US MEC) Category 3 classifications. These include a history of PID only if followed by an intrauterine pregnancy, as subsequent fertility suggests reduced actinomycosis risk.[30] [39] Conditions elevating pelvic infection susceptibility, such as multiple sexual partners or inconsistent barrier use without STI screening, warrant caution due to heightened PID likelihood post-insertion.[9] Uterine fibroids or other anomalies partially distorting the cavity may allow placement if imaging confirms adequate space, though expulsion rates rise.[40] Immunocompromised states like HIV without complications or AIDS with treatment permit use (US MEC 2), but active opportunistic infections elevate risks to Category 3.[30] Past ectopic pregnancy or controlled chronic cervicitis may be relative if no active disease persists, balancing efficacy against recurrence potential.[9] Heavy menstrual bleeding prior to insertion is not strictly contraindicated but merits discussion, as the device often ameliorates this symptom.[40] Category Examples Rationale and US MEC Category (where applicable) Absolute (US MEC 4: Unacceptable risk) Pregnancy; active PID; breast cancer; distorted uterine cavity; liver tumor High likelihood of severe complications like sepsis, malignancy progression, or device malposition.[30] [39] Relative (US MEC 3: Risks usually outweigh advantages) History of PID without subsequent pregnancy; partial uterine distortion; increased STI risk Potential for infection or expulsion, but manageable with prophylaxis or monitoring.[30] [9] Guidelines from the CDC and FDA emphasize pre-insertion screening, including STI testing, to mitigate risks in relative cases, with no evidence of systemic bias altering these empirical contraindications derived from clinical trials and post-marketing surveillance.[41] [39] Procedure-related risks Insertion of a hormonal intrauterine device, such as the levonorgestrel-releasing intrauterine system (LNG-IUS), involves trans-cervical placement, which carries mechanical risks including pain, vasovagal reactions, bleeding, and rare but serious complications like uterine perforation or infection. Pain and cramping during and immediately after insertion are common, often described as similar to or more intense than menstrual cramps, and may be managed with analgesics; vasovagal syncope, manifesting as dizziness, nausea, or fainting, occurs in a subset of cases due to cervical manipulation or fundal contact.[9][42] Uterine perforation, where the device or inserter penetrates the uterine wall, is a rare but potentially serious procedural complication with an incidence of 1.1 to 1.4 per 1,000 LNG-IUS insertions; the risk increases with factors such as lactation (up to tenfold higher), postpartum insertion within 4 days to 6 weeks, retroverted uterus, or incomplete uterine involution.[40][43][39] Perforation may occur at insertion or gradually, often requiring laparoscopic removal if the device migrates to the peritoneal cavity, though many cases are asymptomatic and detected incidentally via imaging.[44][45] Early expulsion, typically within the first year and linked to procedural malpositioning or cervical dilation issues, affects 2% to 10% of LNG-IUS users, with higher rates in nulliparous women, adolescents, or those with uterine anomalies; risk factors include immediate postpartum insertion (up to 5% at 6 months) and menorrhagia.[40][46][47] Vaginal bleeding or spotting during insertion is frequent, and cervical laceration from the tenaculum or sound can occur, though rates are not well-quantified and usually minor.[9] The risk of pelvic inflammatory disease (PID) or infection is confined largely to the first 20 days post-insertion, at less than 1% overall, attributable to transient bacterial introduction rather than the device itself; routine antibiotic prophylaxis is not recommended, as meta-analyses show no reduction in PID incidence.[41][46] Failure to successfully insert the device occurs in up to 8.8% of attempts, particularly with inexperienced providers or anatomical challenges, necessitating alternative contraception or repeat procedures.[48] Overall procedural complications arise in fewer than 1% of cases, with provider experience and pre-insertion ultrasound screening mitigating many risks.[9][49] Adverse effects and long-term outcomes Common hormonal and local side effects Menstrual bleeding alterations Hormonal IUDs commonly alter menstrual bleeding patterns due to the local progestin effect on the endometrium, which thins the uterine lining and reduces tissue available for shedding. For higher-dose devices like Mirena and Liletta (52 mg levonorgestrel), amenorrhea rates reach up to 20% within the first year, with many users experiencing significant reduction or cessation of periods over time. Lower-dose variants Kyleena (19.5 mg) and Skyla (13.5 mg) produce milder but still beneficial changes: Initial adjustment (first 3–6 months): Both often cause an increase in bleeding and spotting days, with irregular patterns, prolonged or heavier bleeding possible. This is common and usually the primary reason for early discontinuation. After adjustment (by 6 months to 1 year and beyond): Bleeding/spotting days decrease for most users, leading to shorter and lighter periods compared to pre-insertion baseline. Cycles may remain somewhat irregular. Specific amenorrhea rates (no bleeding/spotting in a reference period): Kyleena: Approximately 12% by the end of year 1, increasing to 20% by year 3 and 23% by year 5. Skyla: Approximately 6% by the end of year 1 (lower due to reduced hormone dose). These patterns result from local endometrial thinning without full ovulation suppression in most users. Individual variation depends on baseline periods and response. Upon removal, bleeding typically returns to pre-use patterns within months. This information is derived from clinical trials and official prescribing information (e.g., FDA labels for Kyleena and Skyla). Hormonal side effects stemming from systemic absorption of levonorgestrel, though at low plasma levels compared to oral contraceptives, include headaches or migraines (approximately 16% incidence in trials), acne, breast tenderness or soreness, mood disturbances, and variably reported weight changes. Ovarian cysts, typically functional and self-resolving, occur in about 12% of users. Observational data indicate a potential elevated risk of depressive symptoms, particularly among adolescent first-time users (hazard ratio up to 2.0 in some cohorts), though randomized trial evidence on causality is limited and incidences remain below 5% for discontinuation due to such effects. Weight changes and effects on libido/sex drive are variably reported. While some users experience decreased libido, potentially due to progestin influence on androgens, studies and reviews indicate mixed outcomes: over half of hormonal IUD users report no significant change in sex drive, with subsets noting increases (e.g., from improved menstrual comfort or contraception reliability) or decreases. Consistent high-incidence decreases lack strong support from controlled trials, and some data suggest neutral or positive effects on sexual functioning compared to other methods. Local uterine effects commonly manifest as abdominal or pelvic pain/cramping (incidence around 5–13% in early use), often transient and linked to initial endometrial thinning or device presence.[10][50] Vaginal discharge or vaginitis may occur in <5% of cases, typically resolving without intervention.[51] These effects are generally milder than those of copper IUDs due to the progestin's anti-inflammatory action on the endometrium, with overall treatment-emergent adverse events related to the device in 18% of participants in recent trials.[52] Discontinuation rates for bleeding or pain side effects range from 5–15% within the first year, decreasing with familiarity and time.[53] Serious complications Uterine perforation occurs when the hormonal intrauterine device penetrates the uterine wall during or after insertion, potentially migrating into the peritoneal cavity. The incidence is estimated at 1.1 to 1.6 per 1,000 insertions based on large cohort studies involving over 300,000 users.[45] Complete perforations, requiring surgical intervention such as laparoscopy for retrieval, account for approximately 51% of cases, while partial perforations may be managed conservatively if asymptomatic.[44] Risk factors include breastfeeding at insertion, postpartum timing within 12 months, and provider inexperience, with rates up to seven times higher in the early postpartum period compared to non-postpartum insertions.[45] Perforation is often asymptomatic and detected incidentally via imaging, but undetected cases can lead to adhesions, chronic pain, or bowel obstruction.[43] Pelvic inflammatory disease (PID) represents a serious infectious complication, primarily linked to bacterial ascension during or shortly after insertion, with the highest risk in the first 20 days. Meta-analyses indicate no significant long-term elevation in PID risk beyond the initial period among users without preexisting sexually transmitted infections (STIs), though absolute risk remains low at under 1% overall.[54] Women with untreated chlamydia or gonorrhea at insertion face substantially higher odds, prompting recommendations for STI screening prior to placement.[30] Severe PID can progress to tubo-ovarian abscess, infertility, ectopic pregnancy, or chronic pelvic pain, necessitating hospitalization and intravenous antibiotics in advanced cases.[55] Ectopic pregnancy, though rare due to the device's high contraceptive efficacy, carries elevated risks if conception occurs with the device in situ, as intrauterine pregnancies are reduced but extrauterine ones may predominate. Clinical data report ectopic rates of approximately 0.02 to 0.1 per 100 woman-years among users, lower than non-users but with potential for rupture if the device embeds in or perforates the fallopian tube.[55] Pregnancies continuing with an intrauterine device present risks of spontaneous abortion, preterm delivery, sepsis, or maternal death, with FDA postmarketing surveillance documenting such outcomes.[39] Other rare serious complications include device embedment into the myometrium, which may complicate removal and require hysteroscopic or surgical extraction, and group A streptococcal sepsis, historically associated with retained devices fostering anaerobic growth. Intracranial hypertension has been reported in postmarketing data, potentially linked to progestin effects, though causality remains unestablished in large trials.[56] These events underscore the need for prompt evaluation of symptoms like severe abdominal pain or fever post-insertion.[57] Oncologic risks The levonorgestrel-releasing intrauterine system (LNG-IUS) is associated with a reduced risk of endometrial cancer, primarily due to its local progestogenic effect that induces endometrial atrophy and suppresses proliferation. A 2024 population-based study reported a 33% lower risk among LNG-IUS users compared to non-users, with the protective effect persisting for up to 10 years post-removal. [58] Similarly, modeling analyses estimate a 50-78% risk reduction at the population level attributable to LNG-IUS use. [59] This protective mechanism supports its off-label use in preventing endometrial hyperplasia in high-risk women, such as those on estrogen therapy. [60] Evidence on breast cancer risk is conflicting, with some studies indicating a modest increase linked to progestin exposure, while others find no association after adjusting for confounders like parity and screening behaviors. A 2025 cohort analysis of long-acting progestin contraceptives reported a 26% elevated risk for ever-users of LNG-IUS, comparable to other progestin-only methods. [61] Conversely, a 2021 meta-analysis of observational data concluded no increased risk, citing moderate-quality evidence and potential detection bias in users due to heightened medical surveillance. [62] A 2023 Danish registry study observed an overall adjusted hazard ratio of 1.24 for breast cancer incidence among LNG-IUS users aged 15-49, though absolute risk remains low given baseline rates. [63] These discrepancies may stem from residual confounding in non-randomized designs, underscoring the need for further randomized data. LNG-IUS use appears neutral or protective against ovarian cancer, with reductions attributed to altered hormonal milieu and potential suppression of ovulation in some users. A Swedish cohort study found a 47% risk reduction after mean 4-year use, alongside decreased incidence of borderline ovarian tumors. [64] However, a 2022 meta-analysis reported a non-significant odds ratio of 0.66, suggesting no strong protective signal relative to non-users. [65] Population-level data indicate up to 32% lower risk overall for intrauterine device users, though differentiation by hormonal type requires caution. [66] For cervical cancer, LNG-IUS does not elevate risk and may confer a slight reduction, possibly via local immune modulation or reduced persistent HPV infection. Recent analyses show a 14% lower incidence among users, aligning with findings for copper IUDs. [58] [67] A 2021 registry study confirmed equivalent rates of high-grade precancerous lesions (CIN3+) between hormonal and non-hormonal IUD users. [68] No peer-reviewed evidence supports increased cervical oncologic risk from LNG-IUS. Effects on bone density and fertility The levonorgestrel-releasing intrauterine system (LNG-IUS) delivers progestin primarily locally within the uterus, resulting in minimal systemic absorption compared to injectable or implantable progestin-only contraceptives.[69] Studies indicate no clinically significant reduction in bone mineral density (BMD) among long-term users. A prospective cohort study of women using LNG-IUS for up to 7 years found stable forearm BMD, with no differences from baseline or compared to non-users, attributing this to preserved ovarian estrogen production despite induced amenorrhea in many cases.[70] Similarly, cross-sectional analyses comparing LNG-IUS users to copper IUD users showed comparable BMD at the forearm, hip, and spine, suggesting the device's localized action avoids the hypoestrogenic effects linked to BMD loss in systemic progestin methods like depot medroxyprogesterone acetate.[71] [72] Adolescent-specific data are limited, but the lack of substantial estrogen suppression with LNG-IUS—unlike with depot formulations—implies negligible risk of impaired peak bone mass accrual.[73] One review of progestin-only contraceptives noted that while systemic options correlate with BMD declines, intrauterine systems do not exhibit this pattern due to their pharmacokinetic profile.[74] Post-removal, any theoretical transient effects resolve without lasting impact, as estrogen levels normalize rapidly. Overall, evidence from multiple observational studies supports LNG-IUS as neutral for bone health in reproductive-age women.[69] [70] Fertility returns promptly after LNG-IUS removal, with conception rates comparable to those in non-users. Systematic reviews report that approximately 80-85% of women achieve pregnancy within 12 months post-discontinuation, aligning with general population fecundity.[75] [76] A pilot study found 81% pregnancy rates at 12 months among prior IUD users versus 70% in controls, with no statistical difference after adjusting for confounders.[77] Duration of prior use does not delay recovery, as plasma levonorgestrel levels drop quickly post-removal, restoring ovulatory cycles without evidence of endometrial or ovarian impairment.[76] [78] Rare delays in conception may stem from underlying age-related or unrelated factors rather than device effects, as longitudinal data confirm no increased infertility risk.[79] In women over 40, 88% conceived within one year after long-term IUD removal, though absolute rates reflect age rather than method.[80] Unlike persistent effects seen with some depot progestins, LNG-IUS reversibility is well-documented, supporting its suitability for women planning future pregnancies.[75] [77] Mechanisms of action Primary contraceptive mechanisms The levonorgestrel-releasing intrauterine system (LNG-IUS), a common hormonal IUD, exerts its primary contraceptive effects through local progestogenic actions confined largely to the uterus and cervix, rather than systemic hormonal suppression akin to oral contraceptives.[5] The precise local mechanism remains incompletely elucidated, but clinical and histological studies indicate multifactorial pre-fertilization interference, primarily by impeding sperm transport and viability.[5][81] Thickening of cervical mucus constitutes the foremost barrier, creating a viscous plug that inhibits sperm penetration into the uterine cavity and fallopian tubes; this effect arises from levonorgestrel's (LNG) localized release, which alters mucus composition and reduces sperm motility and capacitation even if some sperm reach the mucus.[81][5] In users, LNG concentrations in cervical mucus exceed those in serum by orders of magnitude, ensuring targeted spermicidal-like impairment without broad ovulation blockade in most cycles.[18] Sperm survival studies with LNG-IUS prototypes demonstrate reduced capacitation and fertilization potential in vitro, supporting this as a dominant pre-ovulatory mechanism.[5] Although ovulation is inhibited in some but not all women using hormonal IUDs like Mirena (levonorgestrel 52 mg), systemic levonorgestrel levels are low (plateau 150–200 pg/mL initially, declining over time), insufficient for consistent central suppression of ovulation unlike combined oral contraceptives. Studies show: in a 1-year study, approximately 45% of menstrual cycles were ovulatory; in another after 4 years, 75% of cycles were ovulatory. Thus, most women continue to ovulate in the majority of cycles, especially after the first year when hormone release decreases. Amenorrhea, occurring in ~20% by year 1, results from local endometrial thinning and does not indicate absent ovulation—ovarian function often remains normal with preserved estradiol levels and follicular development. Ovulation suppression contributes secondarily in a subset of cycles/users, while primary mechanisms remain local: cervical mucus thickening blocking sperm, endometrial atrophy inhibiting implantation, with fertility rates remaining low even in ovulatory cycles due to upstream gamete barriers. These local effects yield Pearl Index failure rates of 0.1-0.4 per 100 woman-years in typical use, underscoring efficacy driven by adherence-independent mechanisms. Potential post-fertilization effects and debates The levonorgestrel intrauterine system (LNG-IUS) exerts local effects on the endometrium through high intrauterine concentrations of the progestin, resulting in glandular atrophy, stromal decidualization, and diminished epithelial proliferation, which collectively reduce endometrial receptivity.[82][83] These histological changes, observed in biopsies from users, persist over the device's lifespan and are more pronounced than systemic progestin effects, potentially impairing blastocyst attachment if fertilization occurs despite primary barriers like thickened cervical mucus.[84][2] Although LNG-IUS efficacy exceeds 99%, with primary mechanisms inhibiting sperm transport and ovulation in approximately 20-50% of cycles, the endometrial suppression raises questions about secondary post-fertilization actions.[5][2] Animal models and in vitro studies demonstrate levonorgestrel's interference with implantation windows, but direct human evidence of embryo loss attributable to LNG-IUS is limited, as natural pre-implantation attrition rates (up to 30-50%) confound detection in clinical trials.[85] No randomized studies quantify post-fertilization failures specifically, and manufacturers emphasize pre-fertilization dominance based on spermicidal and ovulatory data.[13] Debates center on whether endometrial effects constitute an abortifacient mechanism, defined variably as intervention after fertilization but before clinical pregnancy detection. Pro-life advocates, such as Human Life International, classify LNG-IUS as abortifacient due to implantation prevention, arguing that even rare post-fertilization events equate to embryo destruction.[86] In contrast, organizations like the American College of Obstetricians and Gynecologists (ACOG) assert LNG-IUS is not abortifacient, citing lack of evidence for disrupting established pregnancies and predominant pre-fertilization action, though acknowledging theoretical endometrial roles.[40] A 2022 survey of U.S. physicians found 10% viewed hormonal IUDs as operating via abortion, lower than for copper IUDs (17%), reflecting interpretive divides on pregnancy onset—fertilization versus implantation.[87] These perspectives influence policy, as seen in 2015 Colorado legislative challenges to IUD funding over abortifacient claims.[88] Empirical resolution remains elusive without ethical embryo-tracking studies, underscoring reliance on mechanistic inference over direct causation data.[89] Insertion, management, and removal Insertion procedure The insertion of a hormonal intrauterine device (IUD), such as the levonorgestrel-releasing Mirena system, is performed by a trained healthcare provider using aseptic technique in an outpatient clinic setting, typically without general anesthesia.[10] The procedure takes about 5-10 minutes and involves minimal equipment, including a speculum, uterine sound, tenaculum, and the pre-loaded inserter tube provided with the device.[9] Prior to insertion, the provider obtains informed consent, confirms absence of pregnancy through menstrual history or testing if uncertain, screens for active pelvic infection or other contraindications via pelvic exam, and assesses uterine position and size bimanually.[41] Optimal timing is within 7 days of menstrual cycle onset for immediate contraception, or postpartum within 48 hours, with backup methods required if inserted later.[10][50] The patient is positioned in dorsal lithotomy, and a speculum is inserted to visualize the cervix, which is cleansed with an antiseptic solution like povidone-iodine.[9] A single-tooth tenaculum st